Given the strong association between metabolic dysfunction-associated fatty liver disease (MAFLD), cardiovascular disease and chronic kidney disease, comprehensive risk assessment should extend beyond liver-specific measures to include broader metabolic and vascular risk.

Practical tools are included to support clinicians with screening, risk assessment and structured management in everyday practice, enabling early risk identification and supporting targeted intervention to improve clinical outcomes.